Nimotuzumab plus platinum-based chemotherapyversusplatinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma

Background: Palliative chemotherapy has been the mainstay treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). However, little is known about the efficacy and toxicity of nimotuzumab (NTZ) - a monoclonal antibody drug targeting epidermal growth factor receptor - plus chemotherapy (CT)versusCT alone for these patients. Methods: The database at Cancer Hospital of Chinese Academy of Medical Sciences was queried for patients diagnosed with NPC who received CT with or without NTZ between 2004 and 2018. Treatment compliance, survival outcomes, and adverse effects were compared among these groups. Results: Records of 70 patients with R/M-NPC were reviewed: 21 (30%) received NTZ plus CT (NTZ+CT) and 49 (70%) received CT. CT regimens included gemcitabine plus platinum, taxane plus platinum (TP), and fluorouracil plus platinum. Comparing the CT group with NTZ+CT group, the median follow up was 62 months (range = 3-133)versus59 months (range = 9-117); median progression free survival was 7.5 [95% confidence interval (CI) 6.552-8.381] monthsversus8.5 (95% CI 6.091-10.976) months,p = 0.424; median overall survival (OS) was 25.6 (95% CI 18.888-32.379) monthsversus48.6 (95% CI 35.619-61.581) months,p = 0.017, respectively. Multivariable analysis established treatment group (CTversusNTZ+CT) as an independent prognostic factor for OS (hazard ratio, 0.5; 95% CI 0.255-0.979;p = 0.043). No significant difference with regard to toxicities was observed between the two groups. Among them, a subgroup analysis was performed in 53 (75.7%) patients who received TP with or without NTZ, which showed similar results. Conclusion: Our findings suggested that NTZ+CT provides a novel treatment option and prolongs survival significantly for R/M-NPC.